Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

Initial safety findings at 24 hours post dosing were consistent with studies of COMP360 in other psychiatric conditionsLONDON, Dec. 19, 2023 -- Compass Pathways plc , a biotechnology company...

Related Keywords

Rockville ,Maryland ,United States ,United Kingdom ,New York ,London ,City Of ,Amy Lawrence ,Stephen Schultz ,James Rucker ,Drug Administration ,Icahn School Of Medicine At Mount Sinai ,Psychoactive Trials Group At King College London ,Linkedin ,Psychology Neuroscience At King College London ,Exchange Commission ,Institute Of Psychiatry ,Nasdaq ,College London ,Icahn School ,Mount Sinai ,New York City ,Sunstone Therapies ,Guy Goodwin ,Chief Medical Officer ,Compass Pathways ,Consultant Psychiatrist ,Psychoactive Trials Group ,Breakthrough Therapy ,Innovative Licensing ,Access Pathway ,Securities Act ,Private Securities Litigation Reform Act ,